Why the study?
Does the treatment of cardiovascular risk factors prevent or slow down age-related cognitive disorders and dementia?
Does the treatment of cardiovascular risk factors prevent or slow down age-related cognitive disorders and dementia?
Optimal treatment of cardiovascular risk factors, particularly hypertension, may help prevent or slow down age-related cognitive disorders, though more targeted trials are needed.
May support antihypertensive use to slow cognitive decline; leaves open statin effects and needs confirmatory trials.
Midlife cardiovascular risk factors, including diabetes, hypertension, dyslipemia, and an unhealthy lifestyle, have been linked to subsequent incidence, delay of onset, and progression rate of Alzheimer disease and vascular dementia. Conversely, optimal treatment of cardiovascular risk factors prevents and slows down age-related cognitive disorders. The impact of antihypertensive therapy on cognitive outcome in patients with hypertension was assessed in large trials which demonstrated a reduction in progression of MRI white matter hyperintensities, in cognitive decline and in incidence of dementia. Large-scale database correlated statin use and reduction in the incidence of dementia, mainly in patients with documented atherosclerosis, but clinical trials failed to reach similar conclusions. Whether a multitargeted intervention would substantially improve protection, quality of life, and reduce medical cost expenditures in patients with lower risk profile has not been ascertained. This would require appropriately designed trials targeting large populations and focusing on cognitive decline as a primary outcome endpoint.
No takes yet. Share an insight, caveat, or question.
Monsuez et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: